EUPRAXIA PHARMACEUTICALS INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
EUPRAXIA PHARMACEUTICALS INC. (EPRX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$37.54 million for the 12-month period ending 2025-12-31, per its 40-F filed 2026-03-13.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-13
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$37.54M 40-F · filed 2026-03-13 |
| 2024-12-31 | -$25.50M 40-F · filed 2026-03-13 |
| 2023-12-31 | -$28.81M 40-F · filed 2025-03-20 |
| 2022-12-31 | -$18.93M 40-F · filed 2024-04-01 |